PTC Therapeutics has withdrawn its U.S. filing for Translarna. Find out what this means for Duchenne drug development and FDA expectations.
UTulsa-backed BioReact targets bioprocess inefficiencies with AI analytics. Discover what this investment could change for biopharma development and manufacturing.
Innovent Biologics advances IBI354 into phase 3 first-line HER2-positive breast cancer. Find out what this means for ADC competition and clinical practice.
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.
WHOOP launches Advanced Labs in the UAE with Unilabs, integrating 65 biomarkers into its wearable platform. Explore what this shift means.
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.
Eli Lilly and Company has entered into a definitive agreement to acquire Orna Therapeutics, Inc., gaining access to the biotechnology firm’s circular RNA platform and its clinical trial ready in vivo CAR-T candidate ORN-252 targeting CD19 for B cell driven autoimmune diseases. The deal, valued at up to 2.4 billion dollars in cash including milestone […]
Kirin and Immunosens are developing a urinary IgA self-testing service to visualize immune status. Find out what this changes for consumer immune monitoring.
Agenus’ AACR-IO biomarker data reframes inflammation as a key determinant in cold tumor immunotherapy. Find out why this could reshape checkpoint strategies.
SCIEX integrates Echo MS+ with ZenoTOF 8600 to reshape high-throughput mass spectrometry workflows. Find out why this matters for discovery labs.